Intermittent explosive disorder

Summary

Intermittent explosive disorder (MONDO:0001521) is a disease and 15 clinical trials. Top therapeutic interventions include fluoxetine, guanfacine, and alcohol. A subtype of impulse control disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intermittent explosive disorder
Mondo ID	MONDO:0001521
DOID	DOID:12401
ICD-10-CM	F63.81
ICD-11	295017661
NCIT	C94332
SNOMED CT	231527003
UMLS	C0021776
MedGen	7116
Is cancer (heuristic)	no

Disease family

This is a subtype of impulse control disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › impulse control disorder › intermittent explosive disorder

Related subtypes (6): kleptomania, pyromania, Kluver-Bucy syndrome, pathological gambling, trichotillomania, primary polydipsia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	7
Not specified	4
PHASE4	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00282165	PHASE4	TERMINATED	Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
NCT02048241	PHASE4	COMPLETED	Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
NCT00399698	PHASE3	COMPLETED	Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
NCT05895513	PHASE2	RECRUITING	Pimavanserin and Aggression and Social Cognition.
NCT06118567	PHASE2	RECRUITING	Effect of Nitrous Oxide on Aggression.
NCT06118580	PHASE2	RECRUITING	Neural Correlates During Alcohol Intoxication
NCT06665074	PHASE2	RECRUITING	Inflammatory Challenge in Human Aggression.
NCT00078754	PHASE2	COMPLETED	A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
NCT00127400	PHASE2	COMPLETED	A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED
NCT02055638	PHASE1/PHASE2	COMPLETED	Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
NCT03420222	PHASE2	TERMINATED	Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
NCT06804525	Not specified	RECRUITING	LHC-CIDI-5 in Hong Kong
NCT00667212	Not specified	COMPLETED	Psychotherapy for Intermittent Explosive Disorder
NCT04819230	Not specified	UNKNOWN	A Cognitive Bias Modification RCT for Aggression
NCT06275607	Not specified	UNKNOWN	Maladaptive Anger Treatment

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUOXETINE	4	3
GUANFACINE	4	3
ALCOHOL	4	1
DIVALPROEX SODIUM	4	1
NARATRIPTAN	4	1
NITROUS OXIDE	4	1
PIMAVANSERIN	4	1
RISPERIDONE	4	1
SRX246	2	1